Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 7/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13333001 | 0.83 | CNR2 (0.48) | P2RX7LMNASMN1; SMN2 | |
| SCHEMBL3323465 | 0.79 | P2RX7 (0.69) | P2RX7LMNASMN1; SMN2GPR55MEN1 | |
| SCHEMBL13361615 | 0.78 | CNR1 (0.43) | P2RX7LMNASMN1; SMN2 | |
| SCHEMBL6939158 | 0.76 | P2RX7 (0.82) | P2RX7GAALMNASMN1; SMN2GPR55 | |
| SCHEMBL4492302 | 0.72 | P2RX7 (0.67) | P2RX7LMNASMN1; SMN2 | |
| SCHEMBL6943139 | 0.72 | P2RX7 (0.60) | P2RX7GAACYP2C19LMNASMN1; SMN2 | |
| SCHEMBL4501549 | 0.71 | P2RX7 (0.59) | P2RX7GAACYP2C19LMNASMN1; SMN2 | |
| SCHEMBL4500870 | 0.70 | P2RX7 (0.61) | P2RX7LMNASMN1; SMN2 | |
| SCHEMBL6939404 | 0.70 | P2RX7 (0.72) | P2RX7GPR55 | |
| SCHEMBL6944565 | 0.69 | CYP1A2 (0.54) | P2RX7CYP2C19LMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100120789-A1 | Compound | STERIX LIMITED (GB) | 2010-05-13 | — | — | US | disclosed |
| US-20100120789-A1 | Compound | STERIX LIMITED (GB) | 2010-05-13 | — | — | US | disclosed |
| US-20090042929-A1 | 11-Beta-Hydroxysteroid Dehydrogenase Inhibitors | STERIX LIMITED (GB) | 2009-02-12 | — | — | US | disclosed |
| US-20090042929-A1 | 11-Beta-Hydroxysteroid Dehydrogenase Inhibitors | STERIX LIMITED (GB) | 2009-02-12 | — | — | US | disclosed |
| EP-1861384-A1 | 11-BETA-HYDROXYSTEROID DEHYDROGENASE INHIBITORS | Sterix Limited (GB) | 2007-12-05 | — | — | EP | disclosed |
| WO-2006100502-A1 | 11-BETA-HYDROXYSTEROID DEHYDROGENASE INHIBITORS | STERIX LIMITED (GB) | 2006-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042929-A1 | 11-Beta-Hydroxysteroid Dehydrogenase Inhibitors | HSD3B1, HSD3B2, HSD11B1 | P2RX7 3719/4885GAA 4508/4885CYP2C19 100/4885 |
| US-20100120789-A1 | Compound | NR0B2, NR0B1, NR4A1 | P2RX7 991/4885GAA 4884/4885CYP2C19 153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.